Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 Dose Escalation of Stereotactic Body Radiation Therapy and Concurrent Cisplatin for Reirradiation of Unresectable, Recurrent Squamous Cell Carcinoma of the Head and Neck.
Echevarria MI, Yang GQ, Chen DT, Kirtane K, Russell J, Kish J, Muzaffar J, Otto K, Padhya T, McMullen C, Patel K, Chung CH, Caudell JJ. Echevarria MI, et al. Among authors: kish j. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):341-347. doi: 10.1016/j.ijrobp.2023.04.007. Epub 2023 Apr 25. Int J Radiat Oncol Biol Phys. 2023. PMID: 37105404 Clinical Trial.
Patient-reported outcomes in immunotherapy for head and neck cancer.
Kirtane K, Hoogland AI, Li X, Rodriguez Y, Scheel K, Small BJ, Oswald LB, Muzaffar J, Kish JA, Bonomi M, Bhateja P, Saba NF, Steuer CE, Chung CH, Jim HSL. Kirtane K, et al. Among authors: kish ja. Head Neck. 2023 Jul;45(7):1761-1771. doi: 10.1002/hed.27388. Epub 2023 May 4. Head Neck. 2023. PMID: 37141438
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.
Mell LK, Torres-Saavedra PA, Wong SJ, Kish JA, Chang SS, Jordan RC, Liu T, Truong MT, Winquist EW, Takiar V, Wise-Draper T, Robbins JR, Rodriguez CP, Awan MJ, Beadle BM, Henson C, Narayan S, Spencer SA, Powell S, Dunlap N, Sacco AG, Hu KS, Park HS, Bauman JE, Harris J, Yom SS, Le QT. Mell LK, et al. Among authors: kish ja. Lancet Oncol. 2024 Dec;25(12):1576-1588. doi: 10.1016/S1470-2045(24)00507-2. Epub 2024 Nov 14. Lancet Oncol. 2024. PMID: 39551064 Free article. Clinical Trial.
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
Mascarenhas J, Harrison C, Schuler TA, Liassou D, Garretson M, Miller TA, Mahadevan S, McBride A, Tang D, DeGutis IS, Abraham P, Kish J, Feinberg BA, Gerds AT. Mascarenhas J, et al. Among authors: kish j. Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):122-132. doi: 10.1016/j.clml.2023.09.008. Epub 2023 Sep 29. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37839939 Free article.
Oncogeriatric Developments.
Extermann M, Al-Jumayli M, Sam C, Kish JA. Extermann M, et al. Among authors: kish ja. Gerontology. 2023;69(9):1045-1055. doi: 10.1159/000531559. Epub 2023 Jun 15. Gerontology. 2023. PMID: 37321185 Free article. Review.
Online Delivery of the Individualized Reduction of Falls Intervention for Persons With Multiple Sclerosis Who Use a Wheelchair or Scooter Full-time: A Pilot Study.
McArthur AR, Peterson EW, Sosnoff J, Backus D, Yarnot R, Abou L, Kish J, Steinkellner S, Sandhu A, Rice L. McArthur AR, et al. Among authors: kish j. Int J MS Care. 2023 Mar-Apr;25(2):82-90. doi: 10.7224/1537-2073.2022-044. Epub 2023 Mar 9. Int J MS Care. 2023. PMID: 36923574 Free PMC article.
191 results